Products
Eltivutabart Biosimilar Monoclonal Antibody (CD39) for Research
Cat No.: GMP-Bios-INN-1173
Anti-ENTPD1/CD39 therapeutic antibody (Pre-made Eltivutabart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Eltivutabart (development code TTX-030) is a monoclonal antibody targeting CD39 (ENTPD1). It is developed by Adimab, AbbVie and Trishula Therapeutics for adenocarcinoma, lymphoma, solid tumours. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1173-1mg | 1mg | 3090 |
| GMP-Bios-INN-1173-10mg | 10mg | |
| GMP-Bios-INN-1173-100mg | 100mg | |
| GMP-Bios-INN-1173-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Eltivutabart biosimilar, Whole mAb, Anti-ENTPD1/CD39 Antibody: Anti-ENTPD1/CD39/Ectonucleoside triphosphate diphosphohydrolase 1/ATP diphosphohydrolase (ATP-DPH therapeutic antibody |
| INN Name | Eltivutabart |
| Target | ENTPD1/CD39 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Adimab;AbbVie;Trishula Therapeutics |
| Conditions Approved | na |
| Conditions Active | Adenocarcinoma;Lymphoma;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
